• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recombinant Prefusion Measles and Mumps F and F –HN (H) Glycoproteins for Vaccine Development
The Measles virus (MeV) and Mumps virus (MuV) are highly contagious paramyxoviruses that can be transmitted by respiratory droplets from or on direct contact with an infected person. The resulting diseases can lead to serious complications or death among children. The existing vaccines for MeV and MuV are live attenuated virus vaccines which are administered in two subcutaneous doses at 1 year of age and as early as one month later. Two doses of a combination measles, mumps and rubella vaccine are 97% effective against measles and 88% against mumps. A single dose of a combination measles, mumps, and rubella vaccine is 93% ...
Source: NIH OTT Licensing Opportunities - April 24, 2020 Category: Research Authors: ajoyprabhu3 Source Type: research

Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof
Ebola virus is a large, negative-strand RNA virus composed of 7 genes encoding viral proteins, including a single glycoprotein (GP). The virus is responsible for causing Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever (EHF), in humans. In particular, Bundibugyo (BDBV), Zaire (EBOV), and Sudan (SUDV) species have been associated with large outbreaks of EVD in Africa and reported case fatality rates of up to 90%. Transmission of Ebola virus to humans is not yet fully understood but is likely due to incidental exposure to infected animals. EVD spreads through human-to-human transmission, with infection re...
Source: NIH OTT Licensing Opportunities - March 9, 2020 Category: Research Authors: ajoyprabhu3 Source Type: research

Recombinant Nipah F Proteins and Their Use
Nipah virus is an emerging pathogenic paramyxovirus responsible for sporadic and isolated outbreaks of severe respiratory and neurologic disease in Southern Asia. As a zoonotic virus, disease can manifest in both animals and human with indigenous fruit bats acting as natural reservoirs of the virus. The effects of viral infection vary from acute respiratory distress to fatal encephalitis. There are currently no approved therapeutics or vaccines against the virus, and growing concerns that this highly pathogenic infection has the potential to cause larger epidemics capable of inflicting significant mortality burden.Like the...
Source: NIH OTT Licensing Opportunities - August 21, 2019 Category: Research Authors: ajoyprabhu3 Source Type: research

Neutralizing Antibodies to Influenza HA and Their Use and Identification
The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe. Current standard of care for individuals hospitalized with uncomplicated influenza infection is administration of neuraminidase inhibitors. However, frequent use of such antiviral drugs increases the risk that the virus will develop drug resistance, especially in high-ris...
Source: NIH OTT Licensing Opportunities - October 30, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Human-derived monoclonal antibody for treatment of Ebola virus infection
Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs.Preclinical efficacy studies demon...
Source: NIH OTT Licensing Opportunities - May 22, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa ( “nanobodies”) with several advantages over conventional antibodies...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Synergistic Internal Ribosomal Entry Site (IRES) —MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Many members of theFlaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally forFlaviviridae. This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines claimed in the ...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal Antibodies that Neutralize Norovirus
Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunop...
Source: NIH OTT Licensing Opportunities - January 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research